Stevenage, UK 14 November 2019 — Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 8.40 am GMT in London, UK.
— Ends —
About Achilles Therapeutics
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUSâ„¢ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.
Achilles was founded by lead investor Syncona Ltd and its original shareholders include the CRT Pioneer Fund, UCL Technology Fund, Cancer Research Technology, with the support of UCL Business (UCLB) and the Francis Crick Institute. For further information please visit the Company’s website at: www.achillestx.com
Further information:
Achilles Therapeutics
Dr Iraj Ali — Chief Executive Officer
+44 (0)1438 906 906
media@achillestx.com
Julia Wilson — Head of Communications
+44 (0)7818 430877
j.wilson@achillestx.com
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
Tel: +44 (0) 203 709 5000
Email: achillestx@consilium-comms.com
US Investor Relations — Solebury Trout
Lee Stern
+1 646-378-2922
lstern@troutgroup.com
